Autolus Therapeutics’ (AUTL) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report sent to investors on Wednesday,RTT News reports.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company decreased their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, July 21st. Finally, Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $9.12.

Autolus Therapeutics Stock Up 15.6%

Shares of AUTL opened at $1.56 on Wednesday. The stock has a market capitalization of $415.18 million, a P/E ratio of -1.86 and a beta of 1.87. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00. The company has a 50 day moving average of $1.87 and a 200-day moving average of $1.80.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. On average, sell-side analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in shares of Autolus Therapeutics by 6.9% in the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock valued at $41,992,000 after acquiring an additional 1,746,020 shares during the period. Armistice Capital LLC boosted its position in shares of Autolus Therapeutics by 9.1% in the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock valued at $27,360,000 after acquiring an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd boosted its position in shares of Autolus Therapeutics by 10.5% in the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after acquiring an additional 900,000 shares during the period. Millennium Management LLC boosted its position in shares of Autolus Therapeutics by 91.6% in the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock valued at $3,885,000 after acquiring an additional 790,437 shares during the period. Finally, Atle Fund Management AB boosted its position in shares of Autolus Therapeutics by 130.5% in the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock valued at $2,520,000 after acquiring an additional 625,817 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.